Mario Sznol, MD
Medical Oncology · New Haven, CTNPI 1073501748
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $141,057 of the $156,786 with a category attached, or 90.0%. It is spread thinly across 27 manufacturers, the largest accounting for just 18.5%. Reporting peaked in 2022 at $38,534 and has fallen 91.2% since, to $3,403 in 2025.
Across 111 payments — averaging $1412.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$29K
- Teva Pharmaceuticals USA, Inc.$19K
- Incyte Corporation$19K
- E.r. Squibb & Sons, L.L.C.$18K
- Biontech SE$12K
- Innate Pharma, Inc$8K
- plus $52K from 21 others
Across 272 payments — averaging $9319.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$858K
- Genentech, Inc.$636K
- Merck$450K
- Roche Products Limited$229K
- AstraZeneca$129K
- Springworks Therapeutics, Inc.$66K
- plus $167K from 8 others
What the payments were for
- Consulting fees$141,05790%
- Speaking & faculty fees$12,9508%
- Travel & lodging$1,3511%
- Food & beverage$1,4291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 19 | $29,015 |
| Teva Pharmaceuticals USA, Inc. | 3 | $19,000 |
| Incyte Corporation | 12 | $18,758 |
| E.r. Squibb & Sons, L.L.C. | 20 | $18,109 |
| Biontech SE | 5 | $11,988 |
| Innate Pharma, Inc | 1 | $7,920 |
| Jazz Pharmaceuticals Inc. | 2 | $5,975 |
| Verastem, Inc. | 9 | $5,911 |
| Array Biopharma Inc | 3 | $5,625 |
| Merck | 1 | $5,450 |
| Alkermes, Inc. | 1 | $4,720 |
| Boehringer Ingelheim | 17 | $4,550 |
| Gilead | 1 | $3,400 |
| Sumitomo Pharma America, Inc. | 1 | $2,720 |
| Genentech, Inc. | 1 | $2,145 |
| GSK | 1 | $1,950 |
| Pfizer | 1 | $1,875 |
| Kadmon Corporation LLC | 1 | $1,800 |
| AbbVie | 2 | $1,100 |
| Astrazeneca UK Limited | 1 | $1,000 |
| Sanofi-aventis U.S. LLC | 1 | $900 |
| Partner Therapeutics, Inc. | 1 | $700 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $660 |
| Seagen Inc. | 1 | $599 |
| Anaeropahrma Science, Inc. | 1 | $400 |
| Clinigen, Inc. | 3 | $392 |
| Genentech USA, Inc. | 1 | $127 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$156,786 in reported general payments places this provider in the 85th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 65 | $1,473,925 |
| BraftoviEncorafenib | 17 | $292,392 |
| LenvimaLenvatinib Mesylate | 11 | $267,035 |
| MektoviBinimetinib | 17 | $255,503 |
| MekinistTrametinib Dimethyl Sulfoxide | 15 | $222,962 |
| TafinlarDabrafenib Mesylate | 16 | $217,176 |
| Ondansetron OdtOndansetron | 14 | $464 |
| Levothyroxine Sodium | 22 | $212 |
| Prednisone | 39 | $210 |
| Amlodipine Besylate | 13 | $189 |
| Triamcinolone Acetonide | 14 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Array Biopharma IncBraftovi, Mektovi | $5,625 | $547,89534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 79 medical oncology providers in Connecticut.
Other medical oncology in New Haven
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Francine FossNew Haven$193K
- Anne ChiangNew Haven$158K
- Lajos PusztaiNew Haven$152K
- Howard HochsterNew Haven$133K
- Sarah GoldbergNew Haven$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.